Abstract | PURPOSE: METHODS: Between April and December 2008, 29 patients were administered 40 courses of chemotherapy in each arm. A randomized crossover study was designed. All patients were administered rG-CSF 24 hours after the last day of chemotherapy as a secondary prophylaxis. Complete blood counts as well as peripheral blood progenitor (CD34+) cell levels were measured before G-CSF treatment and on the fifth and the seventh day of treatment. RESULTS: The median duration of neutropenia, FEN, the length of hospitalization, the incidence of FEN, and documented infection was not different between the two rG-CSF treatment groups. Erythrocyte and platelet transfusion rates were also similar. After 7 days, the mean leukocyte (WBC [white blood cell]) and neutrophil count (ANC [absolute neutrophil count]), hemoglobin and platelet levels were not significantly different. However, the CD34+ cell level was significantly higher in the lenograstim group. Lenograstim was also more expensive than filgrastim. No serious side effects were reported for either rG-CSF treatment. CONCLUSIONS:
|
Authors | Neriman Sarı, Klara Dalva, Inci Ergürhan Ilhan |
Journal | Pediatric hematology and oncology
(Pediatr Hematol Oncol)
Vol. 30
Issue 7
Pg. 655-61
(Oct 2013)
ISSN: 1521-0669 [Electronic] England |
PMID | 24050764
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Adjuvants, Immunologic
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
- Lenograstim
- Filgrastim
|
Topics |
- Adjuvants, Immunologic
(administration & dosage)
- Adolescent
- Chemotherapy-Induced Febrile Neutropenia
(blood, prevention & control)
- Child
- Child, Preschool
- Cross-Sectional Studies
- Double-Blind Method
- Female
- Filgrastim
- Granulocyte Colony-Stimulating Factor
(administration & dosage)
- Humans
- Lenograstim
- Leukocyte Count
- Male
- Neoplasms
(blood, drug therapy)
- Neutrophils
- Recombinant Proteins
(administration & dosage)
- Stem Cells
- Time Factors
|